Alpha Tau Medical (DRTS)
(Real Time Quote from BATS)
$2.09 USD
-0.01 (-0.51%)
Updated Jul 25, 2024 12:20 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
DRTS 2.09 -0.01(-0.51%)
Will DRTS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DRTS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DRTS
Is Alpha Tau Medical (DRTS) Stock Outpacing Its Medical Peers This Year?
Best Momentum Stocks to Buy for January 8th
DRTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 8th
Down -20.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Alpha Tau Medical Ltd. (DRTS)
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
Other News for DRTS
Strong Buy Recommendation for Alpha Tau Medical Ltd. on Promising Alpha DaRT Clinical Outcomes and Market Prospects
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
Alpha Tau’s Alpha DaRT Shows Promise in Cancer Therapy
Alpha Tau publishes long-term safety, efficacy data in superficial cancers
option delistings on June 3rd